REG - Nuformix PLC - NXP001 Update

NuformixAnnouncement

18/12/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231218:nRSR0704Xa&default-theme=true

RNS Number : 0704X  Nuformix PLC  18 December 2023

18 December 2023

 

Nuformix plc

 

("Nuformix" or the "Company")

 

NXP001 Update

 

Nuformix receives second NXP001 milestone payment from Oxilio

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing, is pleased to
announce that the Company has achieved the second milestone according to its
updated NXP001 exclusive licensing agreement with Oxilio Ltd ("Oxilio") and
received the associated payment.

Commenting, Dr Dan Gooding, Executive Director of Nuformix, said: "Oxilio is
progressing NXP001 with Nuformix's full support. We are pleased to have
triggered the second milestone payment as per the terms of our updated
agreement. Funds received continue to assist in advancing our core NXP002 and
NXP004 programmes as we progress partnering interactions for these
programmes."

Enquiries:

 

 Nuformix plc
 Dr Dan Gooding, Executive Director                Via IFC Advisory

 Stanford Capital Partners Limited
 Tom Price / Patrick Claridge (Corporate Finance)  +44 (0) 20 3650 3650
 Bob Pountney (Corporate Broking)                  +44 (0) 20 3650 3652

 IFC Advisory Limited
 Tim Metcalfe                                      +44 (0) 20 3934 6630

 Zach Cohen                                        nuformix@investor-focus.co.uk

 

About Nuformix

 

Nuformix is a pharmaceutical development company targeting unmet medical needs
in fibrosis and oncology via drug repurposing. The Company aims to use its
expertise in discovering, developing and patenting novel drug forms, with
improved physical properties, to develop new products in new indications that
are, importantly, differentiated from the original (by way of dosage, delivery
route or presentation), thus creating new and attractive commercial
opportunities. Nuformix has a pipeline of preclinical assets with potential
for significant value and early licensing opportunities.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFDLLFXLLFFBZ